The 8 analysts offering 12-month price forecasts for Trillium Therapeutics Inc have a median target of 21.00, with a high estimate of 28.00 and a low estimate of 14.00. The median estimate represents a +110.95% increase from the last price of 9.96.
The current consensus among 9 polled investment analysts is to Buy stock in Trillium Therapeutics Inc. This rating has held steady since April, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.17
Reporting Date May 07
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.